AR011509A1 - Composicion de vacuna que comprende antigenos de difteria, tetano y tos ferina(pertusis) acelular y su uso para la manufactura de un medicamento util como reforzador de vacuna. - Google Patents

Composicion de vacuna que comprende antigenos de difteria, tetano y tos ferina(pertusis) acelular y su uso para la manufactura de un medicamento util como reforzador de vacuna.

Info

Publication number
AR011509A1
AR011509A1 ARP970105177A ARP970105177A AR011509A1 AR 011509 A1 AR011509 A1 AR 011509A1 AR P970105177 A ARP970105177 A AR P970105177A AR P970105177 A ARP970105177 A AR P970105177A AR 011509 A1 AR011509 A1 AR 011509A1
Authority
AR
Argentina
Prior art keywords
vaccine
diphtheria
tetane
pertusis
reinforcer
Prior art date
Application number
ARP970105177A
Other languages
English (en)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of AR011509A1 publication Critical patent/AR011509A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una vacuna contra la difteria, el tétanos y la tos ferina, que comprende una baja dosis de cada uno de los siguientes: toxoide (D), toxoide tetánico (D)toxoide de la tos ferina (PT), emaglutinina filamentosa (FHA) hipertactina (69K). Lavacun a mantiene una capacidad para prevenir la tos ferina al mismotiempo que muestra una reactogenicidad excepcionalmente baja, también se proporcionan vacunas de combinacion que comprenden antígenos adicionales.
ARP970105177A 1996-11-07 1997-11-06 Composicion de vacuna que comprende antigenos de difteria, tetano y tos ferina(pertusis) acelular y su uso para la manufactura de un medicamento util como reforzador de vacuna. AR011509A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9623233.5A GB9623233D0 (en) 1996-11-07 1996-11-07 Vaccine composition

Publications (1)

Publication Number Publication Date
AR011509A1 true AR011509A1 (es) 2000-08-30

Family

ID=10802615

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105177A AR011509A1 (es) 1996-11-07 1997-11-06 Composicion de vacuna que comprende antigenos de difteria, tetano y tos ferina(pertusis) acelular y su uso para la manufactura de un medicamento util como reforzador de vacuna.

Country Status (30)

Country Link
EP (2) EP0941117B1 (es)
JP (1) JP3980652B2 (es)
KR (1) KR100518044B1 (es)
CN (1) CN1130226C (es)
AR (1) AR011509A1 (es)
AT (2) ATE222773T1 (es)
AU (1) AU710475B2 (es)
BR (2) BRPI9712917B8 (es)
CA (1) CA2271008C (es)
CO (1) CO4910171A1 (es)
CY (2) CY2407B1 (es)
CZ (1) CZ295954B6 (es)
DE (3) DE69715031T2 (es)
DK (2) DK1240905T5 (es)
ES (2) ES2240647T7 (es)
GB (1) GB9623233D0 (es)
HK (2) HK1050473B (es)
HU (1) HU224126B1 (es)
IL (1) IL129530A (es)
LU (1) LU91183I2 (es)
NO (2) NO320186B1 (es)
NZ (1) NZ335384A (es)
PL (1) PL188460B1 (es)
PT (2) PT1240905E (es)
SA (1) SA98181128B1 (es)
SI (2) SI0941117T1 (es)
TR (1) TR199900979T2 (es)
TW (1) TW471971B (es)
WO (1) WO1998019702A1 (es)
ZA (1) ZA979984B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004314A1 (fr) * 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
KR100374813B1 (ko) * 2000-04-07 2003-03-03 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
JP5007425B2 (ja) * 2006-01-30 2012-08-22 財団法人ヒューマンサイエンス振興財団 百日咳ワクチンの安全性評価方法
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
EP2719395A1 (en) 2010-09-01 2014-04-16 Novartis AG Adsorption of immunopotentiators to insoluble metal salts
JP6191082B2 (ja) 2011-03-02 2017-09-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム より低用量の抗原および／またはアジュバントを有する混合ワクチン
CN102363041A (zh) * 2011-11-17 2012-02-29 成都欧林生物科技股份有限公司 不含防腐剂疫苗的制作工艺
RU2014140521A (ru) 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
CN103100081A (zh) * 2012-12-26 2013-05-15 天津康希诺生物技术有限公司 一种多价联合疫苗
SG11201506858SA (en) 2013-03-08 2015-09-29 Crucell Holland Bv Acellular pertussis vaccine
SG11201600709TA (en) 2013-08-05 2016-02-26 Glaxosmithkline Biolog Sa Combination immunogenic compositions
CN114748616A (zh) * 2022-05-23 2022-07-15 中国医学科学院医学生物学研究所 一种成人青少年用无细胞百白破联合疫苗及其制备方法
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
ZA88488B (en) 1987-01-30 1988-10-26 Smith Kline Rit Hepatitis b virus surface antigens and hybrid antigens containing them
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
EP0299108B1 (en) 1987-07-17 1994-05-18 Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH DNA-molecules coding for FMDH control regions and structured gene for a protein having FMDH-activity and their uses
SG48175A1 (en) 1989-07-25 1998-04-17 Smithkline Beecham Biolog Novel antigens and method for their preparation
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
ATE168271T1 (de) 1992-05-23 1998-08-15 Smithkline Beecham Biolog Kombinierte impfstoffe, die hepatitis b oberfläche antigen und andere antigenen enthalten

Also Published As

Publication number Publication date
NO2006005I1 (no) 2006-05-08
DE122005000046I1 (de) 2005-12-29
CY2407B1 (en) 2004-09-10
JP2001503422A (ja) 2001-03-13
ATE222773T1 (de) 2002-09-15
ES2182131T3 (es) 2003-03-01
CZ295954B6 (cs) 2005-12-14
PL333127A1 (en) 1999-11-22
NO2006005I2 (no) 2010-04-12
AU710475B2 (en) 1999-09-23
DK0941117T3 (da) 2002-11-18
PT941117E (pt) 2002-12-31
NO320186B1 (no) 2005-11-07
TR199900979T2 (xx) 1999-07-21
EP0941117B1 (en) 2002-08-28
CN1130226C (zh) 2003-12-10
DE69733285T3 (de) 2010-03-25
LU91183I2 (fr) 2005-09-20
SA98181128B1 (ar) 2006-03-25
TW471971B (en) 2002-01-11
CY2568B1 (en) 2008-07-02
ES2240647T7 (es) 2010-03-31
HK1022638A1 (en) 2000-08-18
BRPI9712917B1 (pt) 2019-12-03
KR100518044B1 (ko) 2005-09-30
HU224126B1 (hu) 2005-05-30
EP1240905B1 (en) 2005-05-11
DE69733285D1 (de) 2005-06-16
EP0941117A1 (en) 1999-09-15
PT1240905E (pt) 2005-09-30
HK1050473B (zh) 2006-03-03
IL129530A0 (en) 2000-02-29
HUP9904287A3 (en) 2001-05-28
CO4910171A1 (es) 2000-04-24
NO992156L (no) 1999-05-04
HUP9904287A1 (hu) 2000-04-28
ES2240647T3 (es) 2005-10-16
PL188460B1 (pl) 2005-02-28
DE69715031D1 (de) 2002-10-02
EP1240905A1 (en) 2002-09-18
NZ335384A (en) 2000-10-27
CN1236321A (zh) 1999-11-24
CA2271008C (en) 2008-07-22
IL129530A (en) 2005-11-20
SI0941117T1 (en) 2002-12-31
CA2271008A1 (en) 1998-05-14
AU5319698A (en) 1998-05-29
KR20000053092A (ko) 2000-08-25
GB9623233D0 (en) 1997-01-08
DE69715031T2 (de) 2003-05-08
DK1240905T3 (da) 2005-07-18
EP1240905B3 (en) 2009-08-26
WO1998019702A1 (en) 1998-05-14
ATE295178T1 (de) 2005-05-15
CZ164099A3 (cs) 1999-10-13
ZA979984B (en) 1998-07-23
JP3980652B2 (ja) 2007-09-26
HK1050473A1 (en) 2003-06-27
DE69733285T2 (de) 2006-01-12
BRPI9712917B8 (pt) 2021-05-25
SI1240905T1 (en) 2005-10-31
DK1240905T5 (da) 2010-01-11
NO992156D0 (no) 1999-05-04
BR9712917A (pt) 1999-12-07

Similar Documents

Publication Publication Date Title
AR011509A1 (es) Composicion de vacuna que comprende antigenos de difteria, tetano y tos ferina(pertusis) acelular y su uso para la manufactura de un medicamento util como reforzador de vacuna.
Lawrence et al. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720
UY26801A1 (es) Composición de vacuna
NO20015073D0 (no) Vaksiner
AR025750A1 (es) Vacunas
DK1276896T3 (da) Epitop-synkronisering i antigen-præsenterende celler
BR9106748A (pt) Vacina de hyopneumomiae micoplasma inativado e metodo de seu uso
CY1114864T1 (el) Συνθεσεις εμβολιου οι οποιες περιεχουν ανοαοενισχυτικο εκδοχο σαπωνινης
ES2597832T3 (es) Vacuna acelular contra la tosferina
DK1725258T3 (da) Kombinationsvacciner med lav dosis Hib-konjugat
ATE119037T1 (de) Influenzaimpfstoff und adjuvanten.
DE69527202D1 (de) Proteinartige adjuvantien
LU91155I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutininine filamenteuse, de pertactine, d'agglutinogènes fimbriaux coquelucheux 2 et 3 et de virus poliomyélitique inactivé type 1, type 2 et type 3.
ES2158108T3 (es) Vacunacion in ovo contra la coccidiosis.
PT1024824E (pt) Composicao de vacina dispersivel solida para administracao oral
CY1110327T1 (el) DTPa ΕΜΒΟΛΙΑ ΒΛΕΝΝΟΓΟΝΟΥ
DE60136928D1 (de) Verwendung von pflanzen-öl-körper in impfstoffverabreichungsysteme
DK365287D0 (da) Fremgangsmaade til dyrkning af bordetella pertussis, pertussis toxoid, pertussis vacciner og fremgangsmaade til fremstilling af pertussis vacciner
ES2079851T3 (es) Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas.
AR023536A1 (es) Vacunas
WO2004002412A3 (en) A method and composition to elicit an effective autologous antitumoral immune response in a patient
Cohen et al. Two injections of diphtheria-tetanus-pertussis-polio vaccine as the backbone of a simplified immunization schedule in developing countries
AR095206A1 (es) Vacuna acelular contra pertussis
CO4700305A1 (es) Vacunas

Legal Events

Date Code Title Description
FG Grant, registration